Thetis Pharmaceuticals Appoints David N. Cook, PhD, to Board of Managers
ESSEX, Conn.— October 2, 2025—Thetis Pharmaceuticals, LLC (“Thetis”), a clinical-stage company developing TP-317, a first-in-class, oral, small molecule Resolvin E1 (RvE1) drug candidate targeting the BLT1 receptor to treat inflammatory bowel disease (IBD) and cancer, today announced the appointment of David N. Cook, PhD, to its Board of Managers.
“We are excited to have Dr. Cook join our Board,” said Gary Mathias, co-founder and CEO of Thetis. “His extensive experience in clinical and corporate development across both IBD and oncology will be invaluable to Thetis as we advance oral TP-317 into a Phase 1b clinical trial in patients with moderate-to-severe ulcerative colitis.”
Dr. Cook is a veteran biotech executive with more than three decades of leadership in clinical development, scientific strategy, and corporate growth. He has served as CEO or CSO at several companies, including Edgewood Oncology, Forma Therapeutics, Seres Therapeutics, Anza Therapeutics, Eligix, and Cerus Corporation. Over the course of his career, he has helped raise more than $1 billion through IPOs, follow-on financings, partnerships, and non-dilutive funding, and played a central role in multiple corporate acquisitions. Dr. Cook has contributed to the development and commercialization of five licensed products. He earned his A.B. in chemistry from Harvard University and his Ph.D. in chemistry from the University of California, Berkeley.
“I am honored to join the Thetis Board and collaborate with such a forward-thinking team”, said Dr. Cook. “Thetis’s unique BLT1 agonist approach holds great promise for patients with IBD and cancer, and I look forward to working with the team to advance TP-317 through clinical development.”
About Thetis Pharmaceuticals
Thetis is a clinical-stage pharmaceutical company focused on developing resolution therapeutics for chronic inflammatory diseases and cancer. Thetis' lead candidate, TP-317, is a first-in-class, oral Resolvin E1 (RvE1) drug candidate that engages the BLT1 receptor to promote tissue and immune homeostasis. In a Phase 1a study, TP-317 was well tolerated and demonstrated target engagement. Thetis is supported by the Helmsley Charitable Trust, the Crohn's & Colitis Foundation, the Kenneth Rainin Foundation, the National Institutes of Health (NIH), and private investors. This institutional support reflects the strength of the scientific foundation and clinical potential of resolution biology as a complementary therapeutic approach in IBD.
Contact Information
Tracy Lessor
SVP, Communications
Thetis Pharma
617-519-9827